Standards for Laboratory Diagnosis of Tuberculosis Professor Brian I. Duerden Inspector of Microbiology and Infection Control, Department of Health.

Slides:



Advertisements
Similar presentations
ISTC Training Modules 2008 Your name Institution/organization Meeting Date.
Advertisements

Your name Institution/organization Meeting Date. Introduction.
Global Consultation on the Implementation of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB M. Akhalaia, MD, Microbiologist, Reference.
Dr R Ramachandran 5 th Joint International Monitoring Mission to Review NTP Thailand 5th JMM Thailand.
CMGS Clinical ScientistTrainees Meeting 28 th November 2009 QUALITY ISSUES IQC, EQA, CPA Gareth Cross Nottingham Regional Molecular Genetics Service.
Microbiology without culture - is this the future? Professor Brian Duerden Inspector of Microbiology and Infection Control, Department of Health.
HICC An Infection Control Committee provides a forum for multidisciplinary input and cooperation, and information sharing This committee should include.
Overview of current case and treatment outcome definitions Malgosia Grzemska TB Operations and Coordination Stop TB Department Consultation Impact of WHO-endorsed.
World Health Organization TB Case Definitions
MDCH STATE LABORATORY TUBERCULOSIS TESTING Specimens/Tests/Reports
Addressing safety and security while delivering an effective microbiology service Brian I. Duerden & Sam Gillanders Inspector of Microbiology and Infection.
Module 11: Clinical guide to Xpert MTB/RIF Global Laboratory Initiative – Xpert MTB/RIF Training Package.
Diagnostic Microbiology and Immunology
ISDH Lab TB Testing Update Lixia Liu PhD MP(ASCP) September 16, 2010.
Pathology – Making a Difference To Patient Safety and Quality K Pendry Consultant Haematologist WWL NHS Trust.
Tuberculosis in the UK 2013 report
CLIA COMPLIANCE. What is CLIA? In 1988 Congress turned its attention to deficiencies in the quality of services provided by the nation’s laboratories.
Modernising diagnostic medical microbiology services Professor Brian I. Duerden CBE,MD Emeritus Professor of Medical Microbiology, Cardiff University.
Laboratory Training for Field Epidemiologists Strengthening Laboratory and Epidemiology Collaboration Introduction May 2007.
Introduction to ISO New and modified requirements.
Pathology Modernisation: The Carter Report and implications
LABORATORIES and DIAGNOSIS of TUBERCULOSIS Assoc. Prof. Alpaslan Alp Hacettepe University Faculty of Medicine Department of Medical Microbiology.
The Policy Company Limited © Control of Infection.
British Society for Microbial Technology The laboratory diagnosis of tuberculosis 25 years of progress D A Mitchison St George’s, University of London.
IIIIIIIIIIIIIIIIII Point of care testing (POCT) Dr K.A.C.Wickramaratne.
1 Module ON-SITE SUPERVISION OVERVIEW. 2 Content Overview What is on-site supervision? Advantages and disadvantages of on-site supervision Organization.
Tuberculosis Egan’s Chapter 22. Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 2 Tuberculosis (TB) The incidence of.
Risk Assessment. Risk As defined by Kaplan and Garrick, risk analysis consists of answering three specific questions: what can happen? what is the chance.
Medical Laboratory Diagnostic Services Careers. Medical Lab Careers Medical Lab careers include: Phlebotomy technician Phlebotomy technician Medical laboratory.
CLINICAL DIAGNOSTIC TB LABORATORY Alexander Sloutsky, Director University of Massachusetts Supranational Reference TB Laboratory Boston, MA.
Revision of new diagnostics for TB
High cost of Xpert MTB/RIF ® testing per tuberculosis case diagnosed at Partners in Hope Medical Center, a public private HIV care clinic in Lilongwe,
Unit 6: Specialised Techniques: Anti-Microbial Resistance Monitoring and Assessment of STI Syndrome Aetiologies #4-6-1.
Step What happens?. Who is responsible? Procedures needed?
TB Methodologies Dr. John G. Magee Regional Reference Centre for Mycobacteriology Health Protection Agency Regional Laboratory, Newcastle upon Tyne.
NAAT Is it Time for a New Option in California?. Background CDC 2009 guidelines recommend NAAT for each patient with suspected TB for whom the test result.
ANALYTICAL PROCESS CONTROL
Quality control & Statistics. Definition: it is the science of gathering, analyzing, interpreting and representing data. Example: introduction a new test.
TB notification.
Ebola preparedness and Response in Lao PDR. Outline Objective The preparedness contingency plan Phase 1: Preparedness Phase 2: Contingency for response.
Principle Diagnostic Microbiology. Concerned with the etiologic diagnosis of infection. Laboratory procedures used in the diagnosis of infectious disease.
ROADMAP TO ACCREDITATION. A PATHCAREKENYA EXPERIENCE By Paul Okwach Pathcare Kenya Laboratories 27 th November 2008.
Dr Justin O’Grady. Zambia is a high burden TB and high HIV setting 44,154 TB cases notified in 2010 – incidence of 462/100,000 pop Approx 48% of pulmonary.
LABORATORY QUALITY MANAGEMENT AS A KEY COMPONENT OF PATIENT MONITORING: THE NYUMBANI DIAGNOSTIC LABORATORY EXPERIENCE Annie P, Susan W, Tresa P, Lihana.
Roundtable. Detection and treatment of TB Andrew Black.
Peter Cegielski, MD, MPH Team Leader for Prevention, Care and Treatment Global Tuberculosis Branch Division of Global HIV and TB Reinforcing the Surveillance.
REMoxTB – a microbiological challenge Dr Anna Bateson Dr. Tim McHugh, Robert Hunt, Emma Cunningham (Emily Bongard, Holly Ciesielczuk)
INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS Identification of Mycobacterium tuberculosis complex in clinical specimens of HIV-infected patients at Instituto.
Laboratory diagnoses of infections agents. DIFFERENT TYPES OF AND APPROACHES TO CLINICAL SAMPLE COLLECTION.
TB – LABORATORY INVESTIGATIONS by Dr. Zubaidah Abdul Wahab Datin Dr. Ganeswrie Raj 1.
Article review Rapid Molecular Detection of Tuberculosis and Rifampin Resistance [MTB-RIF test] Catharina C. Boehme, M.D., Pamela Nabeta, M.D., Doris Hillemann,
CDC and support for Point of Care Testing Accreditation Muthoni Junghae CDC-Kenya LAUNCH OFF POINT OF CARE TESTING ACCREDITATION PROGRAM PANAFRIC HOTEL-18TH.
Control of tuberculosis in Serbia:
Horace Gumba KEMRI-Wellcome Trust Research Programme
World Tuberculosis Day 2014
Outbreak Investigations
This is an archived document.
Nucleic Acid Amplification Test for Tuberculosis
Rapid diagnosis of pyrazinamide-resistant multidrug-resistant tuberculosis using a molecular-based diagnostic algorithm  S.O. Simons, T. van der Laan,
Shaimah Al-Failakawi Al Amiri Hospital Laboratory Quality Manager
World Tuberculosis Day 2014
Further explorations of surveillance data: case detection (all cases vs. bacteriologically confirmed, All strategies) Good afternoon. I will give a brief.
Module 9 Recording and reporting culture results
Introduction To Medical Technology
Goal Objectives Expected Outcomes
Deciphering TB Lab Reports
11 iii. Define management and supervision roles and responsibilities
Communicable Disease Surveillance Centre, London
Ebola Facts October 15, 2014.
Laura Lane, Epidemiologist
Presentation transcript:

Standards for Laboratory Diagnosis of Tuberculosis Professor Brian I. Duerden Inspector of Microbiology and Infection Control, Department of Health

TB diagnosis and management depend upon a reliable and prompt laboratory service

Guidance and Standards National SOP –How to do the tests NICE guidance –How to manage the patient DH programme DH programme –What service should be delivered –3 working groups

TB monitoring and laboratory services working group Surveillance standards Standards for laboratory diagnosis –Current best practice –Simple and straightforward –Not replicate or replace the National SOP

Standards to cover Samples Transfer to laboratory Immediate tests –Microscopy Culture, isolation and identification Laboratory facilities and expertise Transport Susceptibility testing Molecular fingerprinting/typing Notification PCR detection of Mtb Immunodiagnostic tests Histopathology

Samples Type of sample –Sputum (resp. sample), CSF (spinal/para- spinal/intra-cerebral), gastric washings, lymph nodes (tissues), urine, faeces Number of samples –2 or 3 for sputum? Consecutive days. –Early morning or any time? –True LRT specimen Documentation

Transfer to laboratory Within 24h (or 1 working day, max 48h) –Minimise overgrowth –Maintain AFB character Potentially infected clinical sample –Routine procedure

Immediate tests Microscopy –Auramine fluorescent staining –6-day service (not on call) –Perform microscopy and issue result within 24h (1 working day) of receipt –Telephone positive result to senior member of clinical team –Notify lead TB nurse, lead clinician, CCDC Accreditation; IQC programme; satisfactory EQA performance; staff CPD/peer review

Culture, isolation and identification Automated liquid culture on all samples –Set up within 24h of receipt (6 day service) –Plus conventional solid culture Send all isolates to RCM on day found to be positive –Reach RCM within 24h Complete identification of most mycobacterial isolates within 21 days

Identification and reporting NAAT (PCR, LCR) or hybridisation gene probe for Mtb complex –On the day culture shows positive OR –Within 24h of receipt at RCM Other probes and/or phenotypic tests Report on day of test to –Senior member of clinical team –Lead TB nurse, lead TB clinician, CCDC

Laboratory facilities and expertise Safety – Category 3 for culture –HSE approved –Contingency plan for accidental dispersal –Continuity plan for closure Accredited –IQC programme, satisfactory EQA Sufficient number – daily service, competence Named Consultant and BMS for advice

Transport Samples –Potentially infected samples (routine) Positive cultures –Category A but exemption to treat as B for clinical and diagnostic purposes UN 3373 – marked Diagnostic or Clinical P650 packaging Do not send by Royal Mail

Susceptibility testing Complete within 30 days of initial receipt of clinical sample for primary agents –Isoniazid, rifampicin, pyrazinamide, ethambutol Takes days by liquid proportion (automated) or resistance ratio Molecular detection –Rifampicin within 24h if MDRTB suspected –Isoniazid under development Done at RCM with accreditation, IQC, EQA

Molecular fingerprinting/typing ALL ISOLATES –15-loci MIRU-VNTR Mycobacterial Interspersed Repetitive Units – Variable Number Tandem Repeats –Results to national database –Other techniques as appropriate Done at RCM

Laboratory notification HPA –Via CoSurv from laboratory that identifies a positive culture –Confirmation of positive from RCM within 24h (1 working day) of receipt –RCM reports culture and susceptibility results to MycobNET within 24h of report to clinician

PCR detection of Mtb Not routine Available from RCM for particular samples –High suspicion –Definitive diagnosis deemed to be urgent –Liaise in advance – Consultany Microbiologist to RCM

Immunodiagnostic tests Interferon γ (QuantiFERON-TB Gold) Activated specific T-cells (T-SPOT.TB) –Standard under development Which patients? How long should it take? Who provides it? What do the results mean and who interprets them?

Histopathology Report within 3 days of receipt Inform the Microbiology service –Ensure same reporting as for positive microscopy and culture results Send autopsy samples to Microbiology without formalin!! [Role of PCR to be determined]

Implementation of standards Local responsibility –What is done where? Microscopy; culture; identification –What throughput is needed? –Equipment – cost-effectiveness –Personnel Maintain skills; CPD; peer review Named individuals for advice Back-up and cover –IQC, EQA

Standards for Quality Only do what you can do properly!